Back to search

National and Kapodistrian University of Athens

Μελέτη και αξιοποίηση των λειτουργικών ιδιοτήτων των μεσεγχυματικών βλαστικών κυττάρων διαφόρων πηγών

Abstract

dc:description

Lentiviral γ-globin vectors were initially introduced and are constantly beingimproved as a potentially efficient tool for thalassemia gene therapy. The choice of γ-gene as a therapeutic transgene is based on its anti-sickling effect and its ability topair with the α-globin chains, generating functional HbF. However, their use has oftenbeen hampered by low titers, variable expression and gene silencing. To addressthese issues, previous studies in our lab have successfully developed a series ofoncoretroviral vectors, containing the HPFH-2 enhancer combined with the -117activating Greek mutation of the Aγ-gene promoter and the HS-40 enhancer of the α-globin gene locus, that exhibited high level of Aγ-gene expression with absence ofsilencing. The purpose of this PhD thesis was to develop novel SIN (Self-Inactivating) lentiviral vectors carrying the afore-mentioned regulatory elements andto further evaluate them in a MEL-585 cell-line (Murine ErythroLeukemia- 585), aswell as to assess their therapeutic capacity both in vivo in a β-thalassemia mousemodel and in vitro using CD34+ hematopoietic progenitor cells from β-thalassemiahuman patients. The main goal of this study was to set the ground for a futuresuccessful clinical trial for β-thalassemia gene therapy.• Aim 1: Construction of SIN lentiviral vector GGHI and assessment of itstransduction efficiency in MEL-585 cell-line.In particular, the novel LCR-free, SIN γ-globin lentiviral vector (LV), designated asGGHI is a 3rd generation LV that carries an Aγ-globin gene driven by the Aγ promoterwith the -117 activating HPFH mutation in a reverse orientation relative to the HIVtranscription start site. The HPFH-2 and HS-40 enhancer elements are located at the3´ and the 5´ ends of the transgene, respectively. To reduce repressive chromosomalposition effects on vector expression and to diminish variegation in transgeneexpression, the full length cHS4 chromatin insulator was also included in the GGHIvector. GGHI virus was produced by transient co-transfection of HEK-293Tpackaging cell line with the 4-plasmid system and concentrated 100-fold byultracentrifugation.The MEL-585 cells were transduced with the concentrated virus atserial dilutions and following the induction with hemin and HMBA towards anerythroid phenotype, the functional titer was estimated by FACS. The assessment ofthe stability of GGHI was performed with Southern hybridization using radio-labelledprobe in genomic DNA isolated from transduced MEL-585 cells at serial dilutions.Furthermore, individual MEL clones tranduced at a MOI=1-100 were assessed for Aγ-Abstractxxxiiiglobin gene expression at protein level with FACS and at RNA level with Real TimePCR.Results of Aim 1: The mean functional titer of GGHI vector was calculated tobe 2×108 Transduction Units/ml (TU/ml), following 100-fold concentration withultracentrifugation. The proviral integration of GGHI was intact (10kb) with nodetectable rearrangements as documented in the genomic DNA of transduced MELcells at serial dillutions. GGHI is capable of inducing high levels of Aγ-globinexpression in a pancellular manner, as calculated by FACS analysis using an anti γ-globin antibody at 9 discrete MEL-585 clones, following induction towards anerythroid phenotype. The net mean fluorescence intensity (MFI) was calculated697±347.9, while there was no expression in undifferentiated cells. Also, RNA wasisolated from the above clones and was used to determine Aγ-globin expressionlevels. Our results show that GGHI can induce Aγ-globin expression at282.1±491.18% per copy of mouse α-globin with an average VCN/cell=1.52. Overall,GGHI can efficiently induce high levels of Aγ-globin, in an erythroid-specific andpancellular manner with no signs of rearrengements and in most casesindependently of integration site.• Aim 2 In vitro assessment of the therapeutic potential of GGHI lentiviral vectorat CD34+ haematopoietic progenitor cells isolated from thalassemic patients.Thalassemic CD34+ haematopoietic progenitor cells were isolated from BM orperipheral blood from human patients suffering from β-thalassemia (n=20). Thesecells were cultured in appropriate serum-free medium enriched with cytokines andthen divided into two subpopulations; one was transduced with vector GGHI at a MOI100 for 18 hours, whereas the second was mock-transduced and served as control.Post transduction, CD34+ cells were further cultured, either in semi-solidmethylcellulose medium for 15 days, in order to form BFUe colonies, or in liquiderythroid culture for 18 days so as to promote the differentiation towards a matureerythroblast stage. Ideal culture conditions that support erythroid differentiation anddo not interfere with the exogenous HbF expression were first monitored in normalCD34+ cells from BM or Cord Blood (CB). 15 to 20 individual BFUes per patient ineach experiment were analyzed by semiquantitative PCR using vector-specificprimers, so as to estimate the transduction efficiency and the mean VCN/cell.Furthermore, at liquid erythroid culure level, the differentiation of CD34+ cells wasestimated by: using antibodies against the erythroid marker Glycophorin A, while theproliferation rate and the orthochromatic erythroblasts counts were assessed onAbstractxxxivcytospins. HbF expression, at erythroid liquid culture was further assessed at proteinlevel by FACS, as the percentage of differentiated cells that express HbF and HighPressure Liquid Chromatography (HPLC) to measure HbF expression. Attranscription level Real Time-PCR was employed. Finally, FACS analysis usingantibody against Annexin-V was performed to estimate the percentage of apoptosisin erythroblasts transduced with GGHI from liquid cultures compared to mocktransduced cells.Results of aim 2:Typical yield from bone marrow contained 1-2 × 106 CD34+ cells, while the yield froman initial volume of 20ml of peripheral blood ranged from 104 to 4 × 105 CD34+ cells.At BFUe clonal level, GGHI vector shown to have a transduction efficiency of 40.3%and a mean VCN/ cell of 1.1 per patient. The in vitro model of human erythropoiesisrecapitulated efficiently the pattern of hemoglobin expression, which seemed to beassociated with the developmental stage of the originating primary source(26,7±19,9%) and was determined to be three times lower relative to the in vivopercentage (67.52±41.56%), as calculated with HPLC from thalassemic patients.Therefore, the increase in HbF and the concomitant phenotypical correctionobserved in erythroid cultures is exclusively due to GGHI vector and the exogenousexpression of HbF. A higher percentage of differentiated cells was measured inGGHI transduced cells compared to mock transduced (GGHI cells: 25.2%, Mock:14.5%, p=0.00077), as well as a higher proliferation rate on the 17th day of erythroiddifferentiation in liquid culture (GGHI cells: 200%, Mock: 32%). Moreover, correctedcells exhibited an increased HbF expression relative to mock-transduced cells as aaverage outcome of all patients, which were statistically significant both in the case ofF positive cells (%HbF: GGHI κύτταρα: 51.6%, Μάρτυρας: 47.3%, p=0.09) and theMFI (GGHI κύτταρα: 449, Μάρτυρας: 409.4, p=0.005). Cell lysates from liquidcultures from all experiments were subjected to HPLC and under the specifiedexperiment conditions, GGHI-transduced CD34+ cells exhibited high γ-globin chainsproduction compared to mock transduced control cells with a mean increase 32.9%(p=0.001) from all patients. This HbF increase in protein level was further confirmedin transcription level, where a 29.1 fold increase was observed in GGHI transducedcells versus mock. In addition, GGHI transduction of thalassemic CD34+ cells canresult in statistically significant decrease in apoptosis rate, characteristic ofthalassemia. More precisely, transduction with GGHI resulted in a 50% reduction ofapoptosis, as the mean MFI in control cells was 106.6 versus 50.2 in transducedcells (p=0.007) and a mean 27.2% reduction in the percentage of apoptotic cells(p=0.007). These data were also assessed separately for β+ and β0 patients. Overall,Abstractxxxvthese findings taken together, demonstrate that GGHI is a novel SIN lentiviral vectorcapable of inducing high levels of HbF, folowing transduction of CD34+ cells withaugmented transduction efficiency even at low VCN/cell. Also, the ability tosignificantly restore the thalassemic phenotype, providing new and promisingperspectives in the field of globin gene therapy• Aim 3: In vivo assessment of the therapeutic potential of GGHI LV in a β-thalassemia mouse model.Bone marrow (BM) cells isolated from a mouse model of β-thalassemia (th3/+) werecultured in appropriate medium supplemented with cytokines and then transducedwith GGHI at different MOIs 20, 50 and 100. In order to determine the transductionefficiency and the VCN/cell of GGHI at differents MOIs, transduced BM cells weresubsequently cultured in a methylcellulose medium supplemented with cytokines thatpromotes the formation of BFUe colonies. Prior to a successful conditioning regimenfor BM transplantation (BMT), various combinations of myelosuppressant (Bu,Busulphan) and immunosupressants (Cy, Cyclophosphamide, CsA, Cyclosporin)were evaluated, so as to confer phenotypical correction of mouse β-thalassemia.Post BMT, peripheral blood was collected at monthly time intervals from the recipientmice in order to determine levels of HbF with FACS and evaluate the correction ofhematological parameters and the morphology of erythrocytes on blood smear.Results of aim 3: GGHI vector is capable of transducing th3/+ BM cells with100% efficiency at a MOI=50 and a mean VCN/cell=1.1. The combination of Bu (totaldose of 80mg/kg) and Cy (200mg/kg) pre-BMT and CsA (250μg/kg/dose) post-BMTfor prophylaxis was shown to provide sufficient immunosuppression along with 56%engraftment, as calculated with PCR with vector-specific primers at BM isolated fromtranspanted mice (n=9). No toxic side effects were observed as serum creatininlevels were within normal range (n=7). A high but transient expression of HbF wasdocumented at 7-10 weeks post BMT in the peripheral blood of transplanted mice,with a mean value of 70% (n=15). This HbF expression was accompanied by acorrection at the hematological parameters ((HCT- th3/+: 25.3%, th3/+/GGHI: 32.4%,p=0.0025, RBC- th3/+: 6.54x106 cells/μl, th3/+/GGHI: 8.34 x106 cells/μl, p=0,0001,HGB- th3/+: 9.19 g/dl, th3/+/GGHI: 10.46 g/dl, p=0,01) and a phenotypical correctionat RBC morphology, as observed on stained blood smear. Therefore, GGHI vectorcan efficiently transduce th3/+ BM cells and ameliorate β-thalassemia in vivo, asdocumented by phenotypical improvement of RBC morphology and correction ofhematologic parameters. The transient expression, though suggests that additionalissues of low engraftment of long term repopulating hematopoietic stem cells in theAbstractxxxvispecific animal model need to be addressed before full correction of β-thalassemiacan be achieved

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Georgomanoli, Maria
  • Γεωργομανώλη, Μαρία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/29586

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Georgomanoli, Maria; Γεωργομανώλη, Μαρία. Μελέτη και αξιοποίηση των λειτουργικών ιδιοτήτων των μεσεγχυματικών βλαστικών κυττάρων διαφόρων πηγών. National and Kapodistrian University of Athens, 2012. http://hdl.handle.net/10442/hedi/29586